

What are V20 and V5 and how do we reduce dose to normal lung?

Dr Anusheel Munshi Senior Consultant, Radiation Oncology, Fortis Memorial Research Institute, Gurgaon

anusheel.munshi@fortishealthcare.com

Lung cancer radiotherapy

> RT for lung cancer getting increasingly sophisticated

- Usually addition of concurrent chemotherapy in radical treatment of locally advanced tumours
- Side effects tend to increase with poor lung function patients and addition of chemotherapy.
- > Need to identify parameters to preempt / reduce toxicity
- V 20 and V 5 are two such parameters



POSITIONING AND IMMOBILIZATION

- Immobilization done in supine position
- Arms: Lateral/ Above head
 Above head
 Arms: Lateral/ Above head
 Arms: Lateral
- Neck: Neutral position and chin to SSN distance to be recorded
- Normal breathing
- Various immobilization boards can be used for better reproducible positions including Vaclocks



>Contrast iv (with automatic injector if available)

≻Thin CT slices (3-5 mm) preferable

➢ Cricoid cartilage to L2 region

Must to include entire volume of both lungs in the scan



Lung as an OAR



Volumes while contouring lung as OAR

- Need to select the optimal CT window settings (Lung window)
- ➤ W = 1600 and C=-600 for parenchyma
- Contour each lung separately
- Contour GTV, CTV and PTV
- Using Boolean function , generate lung OAR

Lung OAR= (Left lung + Right Lung) - PTV



Bilateral lung minus PTV(Or GTV)









Basic Definitions

> V 20 = Volume of (B/L lung – PTV) receiving 20 Gray OR MORE

Total volume of B/L Lung – PTV

(represents intermediate dose area)

\geq V 5 = Volume of (B/L lung – PTV) receiving 5 Gray OR MORE

Total volume of B/L Lung – PTV

(represents low dose area)



Normal tissue constraints for Lung

✓ V 20 <35%✓ V 5 < 60%



- Represents area of lung receiving low /very low dose RT
- ➢Gained in importance in IMRT era
- Especially important in techniques such as VMAT and Tomotherapy which give rotational therapies
- Another way to emphasising that low dose areas with IMRT are as equally important.



Dose/Volume constraints

Dose limits for OARs	3D-CRT (RTOG 0617)	3D-CRT (RTOG 0972/CALGB 36050)	SBRT (RTOG 0618, 3 fx)	SBRT (ROSEL European trial, 3 or 5 fx)
Spinal cord (point dose)	Point dose \leq 50.5 Gy	Any portion \leq 50 Gy	\leq 18 Gy (6 Gy/fx)	18 Gy (3 fx) 25 Gy (5fx)
Lung	Mean lung dose ≤ 20 Gy, V ₂₀ $\leq 37\%$	$V_{20} \le 35\%$	$V_{20} \le 10\%$ *	V ₂₀ <5-10% [†]
Esophagus	Mean dose ≤34 Gy	Not limited	\leq 27 Gy (9 Gy/fx)	24 Gy (3 fx) 27 Gy (5 fx)
Brachial plexus (point dose)	≤66 Gy	Not limited	\leq 24 Gy (8 Gy/fx)	24 Gy (3 fx) 27 Gy (5 fx)
Heart [‡]	≤60, ≤45, ≤40 Gy for 1/3, 2/3, 3/3 of heart	≤60, ≤45, ≤40 Gy for 1/3, 2/3, 3/3 of heart	\leq 30 Gy (10 Gy/fx)	24 Gy (3 fx) 27 Gy (5 fx)
Trachea, bronchus	Not limited	Not limited	\leq 30 Gy (10 Gy/fx)	30 Gy (3 fx) 32 Gy (5 fx)
Ribs Skin	Not limited Not limited	Not limited Not limited	Not limited [§] ≤24 Gy (8 Gy/fx)	Not limited Not limited



Seminal Publication – V 20

Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume

histogram analysis for pneumonitis after 3D treatment for

non-smallcell lung cancer (NSCLC). Int J Radiat Oncol Biol

Phys 1999;45:323-329.



Quiz time

If we use B/L lung Minus GTV (instead of B/L lung minus PTV), V 20 shall

≻A) Fall

- ➢ B) Increase
- ≻ C) Variable effect
- ➤ D) No effect

>Ans: B) Increase



V 20 and V 5



Elevated V 20 and V 5

- Truly elevated V 20 and V 5
 - ► Large PTV
 - ► Poor planning
- Spurious elevation of V 20 and V 5
 - Lung not contoured properly (portions left out)
 - Incorrect window used
 - PTV not subtracted out from bilateral lungs



Means to reduce V 20 (3D CRT)

Need to have a good measure of tumour location and likely volumes

Lower lobe tumours likely to have worse dosimetric parameters

Need to place appropriate beams(beam angles, number)

> Special arrangements in specific tumour positions



Suggested tip for central tumour of lung /esophagus



© Dr Anusheel Munshi

tis

Suggested tip for large volume central tumour of lung /esophagus

Keep beam arrangement in a predominantly AP PA direction

© Dr Anusheel Munshi

Means to reduce V 20

- Use IMRT instead of 3 DCRT in appropriate cases
- Use of advanced strategies like gating/tracking/breath hold (it shall decrease the PTV and thereby decrease the zone that get 20 Gray)
- Use of ABC device
 - ► PTV smaller
 - Simulation and treatment in inspiratory position
 - Lungs inflated
 - Lung volume increases and hence denominator more, V 20 falls



DOSE AND VOLUME REDUCTION FOR NORMAL LUNG USING INTENSITY-MODULATED RADIOTHERAPY FOR ADVANCED-STAGE NON-SMALL-CELL LUNG CANCER

HASAN MURSHED, M.D.,* H. HELEN LIU, PH.D.,* ZHONGXING LIAO, M.D.,* JERRY L. BARKER, M.D.,* XIAOCHUN WANG, PH.D.,* SUSAN L. TUCKER, PH.D.,[†] ANURAG CHANDRA, M.D.,* THOMAS GUERRERO, M.D., PH.D.,* CRAIG STEVENS, M.D., PH.D.,* JOE Y. CHANGE, M.D., PH.D.,* MELINDA JETER, M.D.,* JAMES D. COX, M.D.,* RITSUKO KOMAKI, M.D.,* AND RADHE MOHAN, PH.D.*

*Division of Radiation Oncology and [†]Department of Biomathematics, University of Texas M. D. Anderson Cancer Center, Houston, TX

➢ 41 patients of NSCLC

> 3 D CRT and IMRT plans(9 F, equidistant, coplanar, generated)

Target, isocentre and prescription same as 3 D CRT

Parameter	3D-CRT	IMRT	р
Thoracic normal tissue V_{s} (cm ³)	5658 (3040-11596)	6929 (2759-10788)	0.006
Thoracic Normal Tissue V ₁₀ (cm ³)	4905 (2550-8751)	4931 (2066-8722)	0.636
Thoracic Normal Tissue V ₂₀ (cm ³)	3919 (1919-6776)	3398 (1509-6535)	0.001
Thoracic Normal Tissue V ₃₀ (cm ³)	3212 (1560-5489)	2673 (1242-5402)	< 0.0001
Thoracic normal tissue V_{40} (cm ³)	3213 (1560-5489)	2673 (1242-5402)	< 0.0001
Thoracic normal tissue integral dose (J)	180 (88-311)	185 (72-13511)	0.781

V 10 and V20 reduced by 7% and 10% respectively



Murshed, IJROBP, 2003

Evolution of Radiation Oncology- Sharp Gunis but a blurred target



Image guided radiotherapy (IGRT)/ 4 D treatments



IGRT-4 D aspects





Planning Target Volume

Target tracking Treatments

> Further ensuring the Planned dose and the treatment dose similarity

> Removal of motion encompassing margins may reduce normal tissue dose

> Reduction in normal tissue dose may facilitate tumour dose escalation

Higher doses delivered to the tumour could result in an improved cure rate



4D CT simulation





C Online CM CAL INVES ADDI	able	Cutoff	Actuarial incidence of lung toxicity of Grade 2 or higher (Common Toxicity Criteria, version 3.0)	<i>p</i> Value (Fisher exact test)	
NSTRA V20it	osi	≤52%	9%	p = 0.003	SCLC
· 20-P	107 6 1	>52%	46%		
V ₃₀ ipsi	osi	≤39%	8%	p = 0.004	4
ME		>39%	38%		MPEO,
RAI MLE	Dipsi	≤22 Gy	7%	p = 0.04	
7) IC	8	>22 Gy	23%		



Effect of Gated/4 D imaging



Conventional

With gated imaging

Fortis

Keall et al Aust Phys Eng Sci Med 2002

ABC

- Device holds the patients breath in a particular phase of respiration
- Usually the mDIBH level chosen 70%to 80% of maximum inspiratory capacity
- Suitable breath hold duration chosen commonly 20 to 25 seconds



ABC

CT scan acquired (approx two breath holds required to scan the thorax/breast area)

Treatment planning and execution(4-6 breath holds treatment)





Breath Holding Times

Breath Holding Time



A Munshi et al, Under reivew



Clinical Oncology 24 (2012) 556-568



Overview

Stereotactic Conformal Radiotherapy in Non-small Cell Lung Cancer — An Overview

A. Munshi*, R. Krishnatry, S. Banerjee, J.P. Agarwal

Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India

Received 2 August 2011; received in revised form 7 February 2012; accepted 27 March 2012

Abstract

Stereotactic conformal radiotherapy is an established technique in treating cranial lesions and has made significant inroads in the treatment of extracranial sites as well. Early stage non-small cell lung cancer is one such site. This overview assesses the results that have been achieved with stereotactic conformal radiotherapy in non-small cell lung cancer so far and compares its efficacy with surgical and other non-surgical modalities. © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Key words: Carcinoma; lung; radiotherapy; stereotactic



Body Fix solution





ABC outcomes

- ▶18 NSCLC patients from RMH , UK
- ➢ Mean reduction in GTV 25% (p= 0.003).
- Compared with free-breathing, ABC reduced
- ≻V(20) by 13% (p=0.0001)
- ≻V(13) by 12% (p=0.001)
- ≻MLD by 13% (p<0.001)

Brada et al IJROBP 2010



Outcomes of Respiratory Gating

- Twenty patients with CT under assisted breath hold at normal inspiration, at full expiration and under free breathing
- ➤13 of 20 patients had GTVs of <100 cm3</p>
- Benefit of V20 reduction only with small tumours (volume of GTV < 100 cm3) and significant tumour motion



Caution!

- V20 and V5 could vary from one planning workstation to another
- Different algorithms may yield variable V 20 and V 5 (Batho, Monte Carlo algorithm)
- Algorithms can be especially important as there is variation in lung density.
- Algorithms derived directly from Monte Carlo, such as superposition-convolution and collapsed cone far superior to algorithms of the past (e.g. the one used in seminal publication)



Drawbacks of V 20/ V 5







Drawbacks of V 20/ V 5

- DVH represents anatomic pulmonary volume, which does not reflect a variety of confounding factors.
- Not a functional parameter (does not take into account lung function)
- Several other factors important in radiation pneumonitis and need to be accounted (PS,concurrent chemo, smoking, age,)



➤V 5 and V 20 are important parameters to see and evaluate during radical radiotherapy of lung cancer

- Need to understand the rationale and benefit of using these parameters
- Be cognizant of the pitfalls of these parameters as well
- Need to rely on a totality of patient/tumour/dosimetric parameters and not one or two factors in isolation

Acknowledgements

- •Fortis Hospital(Gurgaon) Oncology Team
- •Lung Cancer Working Group at TMH





